Medtronic Gains FDA Clearance of UNiD Patient-Specific Rods for Use with CD Horizon™ Solera™ Voyager™ and Infinity™ OCT Spinal Systems

UNiD Patient-Specific Rods: Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) clearance of patient-specific UNiD™ Rods for use with Medtronic CD Horizon™ Solera™ Voyager™ and Infinity™ OCT spinal systems, expanding the utility of the company’s UNiD™ Adaptative Spine Intelligence (ASI) technology.

UNiD Rods are designed for each patient and industrially pre-bent prior to surgery to accurately match an artificial intelligence (AI)-driven pre-operative surgical plan, which is created with UNiD™ ASI technology to precisely align patients’ spines, reducing the risk of malalignment and associated revision surgeries. UNiD Rods are used to treat scoliosis, trauma, tumors, and complex degenerative conditions in adults and adolescent idiopathic scoliosis.

Spine surgery is one of the more complex procedures in healthcare because of the high number of different parameters that must be taken into consideration. In conventional spine surgery, surgeons manually bend spine rods in the operating room, and there can be large variability in outcomes. With the compatibility of UNiD Rods and Medtronic’s spinal systems, surgeons are able to tailor rods, as well as select the Medtronic interbody devices and other hardware that are best suited for their patient’s unique anatomy and sagittal alignment needs. Additionally, surgeons can use advanced navigation and robotics, like the Mazor™ Robotic Guidance System, with minimally invasive patient-specific rods to make procedures more precise and efficient and improve surgical outcomes.

The first surgery combining the CD Horizon Solera Voyager minimally invasive spinal system with patient-specific UNiD Rods in combination with the Mazor platform was performed by Dr. Gregory Poulter, OrthoIndy Hospital, Indianapolis, Ind.

“Being able to integrate powerful complimentary technologies — AI, robotics and patient-specific implants — is the future of spine surgery and will change spine care for the better by streamlining my workflow and reducing surgical uncertainty,” said Dr. Poulter. “I’m not bending rods or increasing OR time with manual execution. Instead, I planned my first case with AI, selected the best hardware for my patient, executed the surgery with Mazor robotic-assisted delivery of the screws and was able to position the rod in 2.5 minutes, resulting in less blood loss and OR time and, most importantly, a predictable and precise alignment for my patient.”

Spine surgery is evolving and becoming increasingly personalized. It is no longer just driven by metal implants and instrumentation, but advanced imaging, navigation, robotics, and pre-operative planning aided by AI. UNiD™ Adaptive Spine Intelligence provides a planning service powered by AI, intra-operative execution, and insightful analytics of surgical results with the ultimate goal of improving clinical outcomes. This game changing solution is easily accessible to any surgeon via a user-friendly UNiD™ HUB platform.

“By combining our widely used spinal systems with UNiD Rods, Medtronic is putting surgeons on the forefront and revolutionizing spine care as the first company to offer a fully integrated solution with unparalleled technologies – AI-driven surgical planning, personalized spinal implants and robotic assisted surgical delivery that work together to advance patient care,” said Dan Wolf, vice president, Medicrea, within the Cranial & Spinal Technologies business, which is part of the Neuroscience Portfolio at Medtronic. “The next era of spine care is in personalized care that integrates the most advanced technologies to offer optimal planning, precision and predictability, so surgeons can do more for their patients.”

SourceMedtronic
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version